Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL


Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”

SHARE